John Coleman, Ph.D., envisions a future where blood types cease to be a primary constraint in life-saving organ transplants and blood transfusions. “Recognizing the urgent need for solutions to these challenges, we have...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Annovis Bio completes enrollment in Phase 3 Parkinson’s trial
Annovis Bio’s (NYSE:ANVS) Parkinson’s disease (PD) Phase 3 clinical trial of its lead compound, buntanetap, reached full enrollment in a record nine months after it began. Since the first patient was dosed in late...
FibroGen flunks Phase 3 in non-ambulatory DMD
FibroGen’s (NASDAQ: FGEN) Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD) on background corticosteroids did not meet the...
Vistagen posts positive Phase 2A study in women with menopausal hot flashes
Vistagen (NASDAQ:VTGN) reported that PH80, one of the company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory Phase 2A study for the...
Marie Mazur appointed chair of PharmaJet board
PharmaJet named Marie Mazur, PharmD, chairwoman of the board, replacing Ron Lowy, who had chaired the board since 2011. “Marie’s experience and leadership will be of great benefit for our company as we are accelerating...
Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director
Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Kaouthar Lbiati, M.D., as an independent director. Dr. Lbiati received a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a...
Check-Cap reviewing strategic alternatives
Check-Cap (NASDAQ:CHEK) is exploring strategic alternatives, such as the sale of all or part of the company, licensing, merger or reverse merger, and has retained Ladenburg Thalmann as an advisor to the company. Check...
iBio expands tech stack with EngageTx; adds TROP-2 bispecific to pipeline
iBio (NYSEA:IBIO) expanded its AI-powered technology stack with the launch of EngageTx, a proprietary T-cell engager antibody panel designed for developing bispecific antibodies for immuno-oncology applications. Through...
Perimeter Medical names Adrian Mendes as CEO; appoints Dr. Josh Vose to board
The board of Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF; FSE:4PC) appointed Adrian Mendes as CEO, effective immediately, succeeding Jeremy Sobotta, who has resigned for personal reasons, effective June 15, 2023...
Research Capital ups Profound Medical to speculative buy; PT to $17.25
Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...
Synlogic initiates pivotal study for phenylketonuria
Synlogic (NASDAQ:SYBX) initiated Synpheny-3, a global, Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU), a rare inherited disorder that causes an amino...
Jazz, Zymeworks present positive pivotal data in BTC
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific...
AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO
Profound Medical (NASDAQ:PROF; TSX:PRN) announced that, with sponsorship and support from multiple physician specialty societies, it has received from the American Medical Association (AMA) three new Current Procedural...
Just a few of the companies we’ve highlighted along the way
